Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acasunlimab + pembrolizumab + chemotherapy
- Development stage
- Unknown
- Lead developer
- Genmab
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Acasunlimab is a bispecific monoclonal antibody (also known as GEN1046 or BNT311, and DuoBody-PD-L1x4-1BB) designed to elicit an antitumor immune response by conditionally activating 4-1BB only when bound to PD-L1. This mechanism aims to enhance T-cell mediated anti-tumor activity while minimizing off-target toxicity. Pembrolizumab (KEYTRUDA) is a monoclonal antibody that blocks the programmed cell death protein 1 (PD‑1), thereby preventing tumor cells from evading immune detection. The combination of acasunlimab and pembrolizumab, with or without chemotherapy, is being investigated for the treatment of metastatic non-small cell lung cancer (NSCLC), particularly in patients who have progressed after prior PD-(L)1 inhibitor and platinum-based chemotherapy[2][3][7]. Acasunlimab was developed by Genmab and BioNTech; pembrolizumab was developed by Merck & Co.
- Brand names
- KEYTRUDA
- Other names
- DuoBody-PD-L1x4-1BBDuoBody-PD-L-1x4-1BBDuoBody-PD-L 1x4-1BB
02
Targets
TNFRSF9 (CD137 extracellular domain)PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on acasunlimab + pembrolizumab + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acasunlimab + pembrolizumab + chemotherapy.